Physician profile
Aaron A Spitz
NPI 1164487674
$38,096.71
in general payments reported to CMS, 2019-2025
25 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $18.19 · 2021: $6,634 · 2022: $809 · 2023: $352 · 2024: $375 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,394 · Honoraria: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.85 |
| Honoraria | $700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $18,887.21 | 2019-2023 | Xiaflex, Aveed |
| Abbvie INC. | $13,646.66 | 2019-2025 | Alloderm, Lupron Depot |
| Metuchen Pharmaceuticals | $2,664.56 | 2019 | |
| Teleflex LLC | $973.21 | 2021-2025 | Barrigel, Urolift |
| Procept Biorobotics Corporation | $251.23 | 2022-2023 | Aquabeam Robotic System |
| Medtronic, INC. | $239.86 | 2021-2022 | |
| Dornier Medtech America, INC | $228.42 | 2025 | Dornier Medtech |
| Astellas Pharma US INC | $172.30 | 2020-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $166.04 | 2023-2025 | |
| Histosonics, INC. | $147.96 | 2024 | |
| Endo USA, INC. | $118.76 | 2024-2025 | Xiaflex, Aveed |
| Myovant Sciences INC. | $99.75 | 2021-2022 | |
| Boston Scientific Corporation | $75.14 | 2021-2023 | Rezum Generator |
| Antares Pharma, INC. | $72.34 | 2022-2025 | Xyosted |
| Progenics Pharmaceuticals, INC. | $60.77 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $53.72 | 2019-2024 | Erleada |
| Accord Healthcare, INC. | $47.24 | 2024-2025 | |
| Telix Pharmaceuticals | $30.52 | 2025 | Illuccix |
| Olympus America INC. | $28.46 | 2022 | |
| Tolmar, INC. | $27.71 | 2023 | |
| Urogen Pharma, INC. | $27.00 | 2022 | |
| Ferring Pharmaceuticals INC. | $23.49 | 2025 | Adstiladrin |
| Urovant Sciences INC | $18.94 | 2022 | |
| Merck Sharp & Dohme LLC | $18.75 | 2025 | Keytruda Qlex, Keytruda |
| Calyxo, INC. | $16.67 | 2025 | Cvac Aspiration System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Spitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.